Group 1 - The company held its 23rd meeting of the 4th Board of Directors on September 4, 2025, to discuss various proposals, all of which were approved unanimously by the attending directors [2][3]. - The board approved a proposal to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance global development strategy and optimize capital structure [2][5][12]. - The issuance of H-shares will not exceed 15% of the total share capital post-issuance, subject to market conditions and regulatory approvals [12][14]. Group 2 - The board agreed on the issuance method, which includes public offerings in Hong Kong and international placements, with specific allocation strategies based on demand and investor qualifications [9][10][19]. - The board approved the use of proceeds from the H-share issuance for global expansion, technology development, capacity upgrades, and general corporate purposes [27][30]. - The company will transition to a foreign-funded joint-stock company after the H-share issuance and listing, allowing it to be publicly listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange [30][32]. Group 3 - The board proposed to cancel the supervisory board, transferring its responsibilities to the audit committee, and to revise the company's articles of association accordingly [78][79]. - The company will appoint a new independent director and adjust the board's specialized committees to enhance governance structure [42][46]. - The board plans to hold a second extraordinary general meeting in 2025 to review the proposals discussed in the board meeting [73].
安徽华恒生物科技股份有限公司 第四届董事会第二十三次会议决议公告